Abstract:
ObjectiveTo investigate the serum levels of soluble ST2(sST2), activin A(ACT-A), and N-terminal brain natriuretic peptide precursor(NT-proBNP), and its clinical significance in the occurrence and development of chronic heart failure(CHF).
MethodsA total of 149 patients with CHF and 50 healthy people were divided into the CHF group and control group, respectively.The differences of the serum levels of sST2, ACT-A, NT-proBNP between two groups, and correlation between three indicators and clinical parameters were analyzed.The ROC curves were used to analyze the predictive value of serum sST2, ACT-A and NT-proBNP in cardiovascular events of patients with CHF.
ResultsCompared with the control group, the serum levels of sST2, ACT-A, NT-proBNP in patients with CHF were significantly higher(P < 0.01), while the Left Ventricular Ejection Fractions(LVEF) was significantly lower(P < 0.01).The serum levels of sST2, ACT-A, NT-proBNP in patients with NYHA grade Ⅳ were significantly higher than those in grade Ⅲ, and which in patients with grade Ⅲ was significantly higher than grade Ⅱ(P < 0.05).The serum levels of sST2, ACT-A, NT-proBNP in patients with CHF were significantly positively correlated with NYHA classification, and negatively correlated with LVEF(P < 0.05), but which were not related to the age, TC, TG, hsCRP, HDL-C, and LDL-C, hs-CRP and HbA1c(P>0.05).The ROC curve analysis results showed that the area under the curve(AUC) of sST2, ACT-A, and NT-proBNP was 0.803, 0.715, and 0.692, respectively.The combined detection AUC of all three was 0.891, and the predicted value of which was higher than that of any single indicator.
ConclusionsThe serum levels of sST2, ACT-A, NT-proBNP in patients with CHF increase, and the expression levels of the three are significantly positively correlated with NYHA classification, and negatively correlated with LVEF.The combined detection in CHF patients has a high predictive value in cardiovascular events.